Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway

Figure 5

Schematic diagram of the role of glibenclamide on NLRP3 inflammasome in the pathogenesis of LPS-induced ALI. Glibenclamide blocked the activation of NLRP3 inflammasome induced by LPS and thus reduced the release of proinflammatory cytokines and then attenuated the lung injury consequently.